Summary
Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.
Plecanatide is being developed by Synergy Pharmaceuticals for the treatment of patients with IBS-C. Following the completion of a successful Phase IIb clinical trial in April 2014, Synergy announced that the Phase III development program for plecanatide was scheduled to be initiated in Q4 2014. The Phase III program, which has been agreed to by the FDA, will consist of two pivotal clinical trials that will evaluate the efficacy and safety of plecanatide at dosages of 3mg/day and 6mg/day during a 12-week treatment period (Synergy Pharmaceuticals, press release, July 8, 2014).
Scope
- Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Plecanatide including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Plecanatide for the top 7 countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, and Japan.
Enquire About Report: http://www.radiantinsights.com/research/plecanatide-irritable-bowel-syndrome-forecast-and-market-analysis-to-2023
Reasons To Buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for IBS.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Plecanatide performance.
- Obtain sales forecast for Plecanatide from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, the UK, and Japan).
About Us
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
For More Information Visit - Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone:1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.
Plecanatide is being developed by Synergy Pharmaceuticals for the treatment of patients with IBS-C. Following the completion of a successful Phase IIb clinical trial in April 2014, Synergy announced that the Phase III development program for plecanatide was scheduled to be initiated in Q4 2014. The Phase III program, which has been agreed to by the FDA, will consist of two pivotal clinical trials that will evaluate the efficacy and safety of plecanatide at dosages of 3mg/day and 6mg/day during a 12-week treatment period (Synergy Pharmaceuticals, press release, July 8, 2014).
Scope
- Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Plecanatide including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Plecanatide for the top 7 countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, and Japan.
Enquire About Report: http://www.radiantinsights.com/research/plecanatide-irritable-bowel-syndrome-forecast-and-market-analysis-to-2023
Reasons To Buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for IBS.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Plecanatide performance.
- Obtain sales forecast for Plecanatide from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, the UK, and Japan).
About Us
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
For More Information Visit - Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone:1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
No comments:
Post a Comment